No surprise FDA Oncology approval expedited to 03/26 as #Rosella trial #SGOAM26 confirms OS benefit with 45% reduction in hazard with nearly double number of patients alive at 18mo mark (27 vs 46%) 🎊 in combo arm of Relacorilant and nab-tax SGO

RAMP201 impacts low grade #ovariancancer even in KRAS wild type. Impressive 12.6mo DOR for KRASm with over 50% of pts still on therapy at 1yr. But wait...the wild types benefit with 7mo DOR and 30% on therapy >1yr. Let's confirm it in #RAMP301

First came Abemaciclib/Fulvestrant by Green et Al in ER positive endometrioid cancers but wait...PFS is promising for cousin Abemaciclib/Letrozole in ph II #GOG3039 at #SGOAM26 with 6mo PFS 56.9% and median of 9.5mo with >50% pts still on at over a year. The GOG Foundation Inc. SGO

Live from #SGOAM26 Plenary Session: Marilyn Huang, MD (UVA Comprehensive Cancer Center) presents a Phase II trial of abemaciclib plus letrozole in recurrent or persistent endometrioid endometrial carcinoma. Key takeaways: • Abemaciclib plus letrozole demonstrated clinically meaningful

April 10, 2026 Big day in #gynonc. Two pivotal studies (KEYNOTE-B96 and ROSELLA) on platinum-resistant recurrent ovarian cancer were published simultaneously in The Lancet—poised to reshape clinical practice. For a space that has long needed breakthroughs, this feels like a

Trastuzumab pamirtecan (DB-1303/BNT323) shows encouraging activity in previously treated, HER2-expressing advanced/metastatic endometrial cancer at #SGOAM26. ✅ Confirmed ORR: 49.3% ✅ Responses seen across HER2 expression levels ✅ Manageable safety profile SGO #gyncancer

SISTER study at #SGOAM26. ✅ First national randomized trial of social support in Black women with high-risk EC ✅ 1:1 peer support improved treatment completion ✅ Supportive care trials in this population are feasible An important report for EC care. SGO #gyncancer

#NRG-GY033 at #SGOAM26: Exemestane + darolutamide + leuprolide acetate in recurrent adult-type ovarian granulosa cell tumor ✅ ORR 6.25%, below the prespecified threshold ✅ Stable disease in 62.5% pts Negative trial. How can hormonal therapy in AGCT be further advanced? SGO

I am honored to have received the Best Basic Science Award at the SGO 2025 Annual Meeting. I am truly grateful for this recognition and will continue advancing research in gynecologic oncology to make a meaningful difference for patients. SGO #CRepHS #WashU

Updated Ph1 data for Sofe-M (LY4170156) in recurrent PROC at #SGOAM26. ✅ ORR 50% in a heavily pretreated cohort ✅ Activity across FRα expression levels, including prior MIRV exposure ✅ Favorable safety, with low neuropathy and no keratopathy Ph3 ongoing! SGO @gyncancer

Emerging data at the #SGOAM26 Plenary: Toon Van Gorp, MD, PhD (UZ Leuven) shares results on combining carboplatin and pembrolizumab with or without bevacizumab in first-line recurrent or metastatic cervical cancer. Key takeaways:
• Robust antitumor activity with ORR ~66%,

Uterine cancer is the fourth most common cancer in women in the US, with an estimated 68 270 new cases and 14 450 cancer deaths projected to occur in 2026. 📄 This Review summarizes the epidemiology, clinical presentation, and diagnosis of endometrial cancer.

We are thrilled to be sharing new clinical data from our first-in-human multicenter open-label study of our folate receptor α (FRα)–targeting antibody-drug conjugate (ADC). Abstract CT306, will be held Tuesday, April 21, 2026 at 2:30 – 4:30 pm Pacific Standard Time (PST).